跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
miR-210
首页
药物
miR-210
miR-210
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
USE OF INHIBITORS OF MICRORNAS IN THE TREATMENT OF LUNG DISEASES
EP 4616905 A1
申请人: INT CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY ICGEB
优先权: 2024
EP
WO
2 件公开
METHODS OF USING MIR210 AS A BIOMARKER FOR HYPOXIA AND AS A THERAPEUTIC AGENT FOR TREATING CANCER
US 2011166200 A1
申请人: ZHANG ZHAN
优先权: 2008
US
USE OF EXTRACELLULAR RNA TO MEASURE DISEASE
US 2011160290 A1
申请人: TEWARI MUNEESH
优先权: 2009
US
Methods for Diagnosing Breast and Lung Cancer Using miR-210 and miR-213
US 2012214689 A1
申请人: CROCE CARLO M
优先权: 2012
US
Application of cycling miR-210 in early diagnosis of hypertension and early warning of target organ injury
CN 104306992 A
申请人: YUEYANG HOSPITAL INTEGRATED TRADITIONAL CHINESE & WESTERN MEDICINE SHANGHAI UNIV
优先权: 2013
CN
Human miR-210 biological knock-down element, construction method and application thereof
CN 105886505 A
申请人: 2ND PEOPLES HOSPITAL SHENZHEN
优先权: 2014
CN
枸杞红素的用途
CN 105969725 B
申请人: 暨南大学
优先权: 2016
CN
Construction method and application of human miR-210-3p interference fragment
CN 109777799 A
申请人: XINYA BIOTECHNOLOGY SUZHOU CO LTD
优先权: 2017
CN
Method of diagnosing and treating acute rejection in kidney transplant patients
US 11685950 B2
申请人: UNIV INDUSTRY COOPERATION GROUP KYUNG HEE UNIV
优先权: 2018
US
Research method of MS-275 acting on acute myocardial ischemia reperfusion injury
CN 111575363 A
申请人: 2ND XIANGYA HOSPITAL CENTRAL SOUTH UNIV
优先权: 2020
CN
第 1 / 2 页
上一页
下一页
药物
反馈